CA2571030A1 - Compositions et methodes pour la prevention et la regulation de l'hypoglycemie induite par l'insuline - Google Patents

Compositions et methodes pour la prevention et la regulation de l'hypoglycemie induite par l'insuline Download PDF

Info

Publication number
CA2571030A1
CA2571030A1 CA002571030A CA2571030A CA2571030A1 CA 2571030 A1 CA2571030 A1 CA 2571030A1 CA 002571030 A CA002571030 A CA 002571030A CA 2571030 A CA2571030 A CA 2571030A CA 2571030 A1 CA2571030 A1 CA 2571030A1
Authority
CA
Canada
Prior art keywords
glucagon
insulin
administered
hypoglycemia
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002571030A
Other languages
English (en)
Inventor
Daniel T. Green
Robert R. Henry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DiObex Inc
Original Assignee
Diobex, Inc.
Daniel T. Green
Robert R. Henry
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diobex, Inc., Daniel T. Green, Robert R. Henry filed Critical Diobex, Inc.
Publication of CA2571030A1 publication Critical patent/CA2571030A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002571030A 2004-06-29 2005-06-27 Compositions et methodes pour la prevention et la regulation de l'hypoglycemie induite par l'insuline Abandoned CA2571030A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58444904P 2004-06-29 2004-06-29
US60/584,449 2004-06-29
PCT/US2005/022812 WO2006004696A2 (fr) 2004-06-29 2005-06-27 Compositions et methodes pour la prevention et la regulation de l'hypoglycemie induite par l'insuline

Publications (1)

Publication Number Publication Date
CA2571030A1 true CA2571030A1 (fr) 2006-01-12

Family

ID=35783298

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002571030A Abandoned CA2571030A1 (fr) 2004-06-29 2005-06-27 Compositions et methodes pour la prevention et la regulation de l'hypoglycemie induite par l'insuline

Country Status (11)

Country Link
EP (1) EP1778266A4 (fr)
JP (1) JP2008505087A (fr)
KR (1) KR20070029276A (fr)
CN (1) CN101001638A (fr)
AU (1) AU2005260025A1 (fr)
CA (1) CA2571030A1 (fr)
IL (1) IL180361A0 (fr)
MX (1) MXPA06014970A (fr)
NO (1) NO20070174L (fr)
WO (1) WO2006004696A2 (fr)
ZA (1) ZA200700708B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012059762A1 (fr) 2010-11-03 2012-05-10 Arecor Limited Nouvelle composition comprenant du glucagon
CN107949374B (zh) * 2015-09-04 2022-04-08 莱迪杜德制药公司 稳定的胰高血糖素溶液
GB201611077D0 (en) 2016-06-24 2016-08-10 Arecor Ltd Novel composition
US11357829B2 (en) 2017-02-03 2022-06-14 Vanderbilt University Systems, compositions and methods for treating diabetes
MX2020000514A (es) * 2017-07-14 2020-08-03 Xeris Pharmaceuticals Inc Metodos para tratar el hiperinsulinismo congenito.
WO2019108640A1 (fr) * 2017-11-28 2019-06-06 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Procédés et kits pour évaluer le métabolisme

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3897551A (en) * 1971-04-05 1975-07-29 Lilly Co Eli Iodoglucagons and process for prolonging the biological activity of glucagon
US5321008A (en) * 1991-01-10 1994-06-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions
BR0316327A (pt) * 2002-11-18 2005-09-27 Pfizer Prod Inc Amidas cìclicas fluorinadas inibidoras de dipeptidilpeptidase iv
US7314859B2 (en) * 2002-12-27 2008-01-01 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia

Also Published As

Publication number Publication date
MXPA06014970A (es) 2007-03-07
EP1778266A2 (fr) 2007-05-02
EP1778266A4 (fr) 2009-09-09
AU2005260025A1 (en) 2006-01-12
IL180361A0 (en) 2007-06-03
KR20070029276A (ko) 2007-03-13
JP2008505087A (ja) 2008-02-21
CN101001638A (zh) 2007-07-18
WO2006004696A3 (fr) 2006-10-26
WO2006004696A2 (fr) 2006-01-12
NO20070174L (no) 2007-03-13
ZA200700708B (en) 2009-03-25

Similar Documents

Publication Publication Date Title
US7655618B2 (en) Compositions and methods for the prevention and control of insulin-induced hypoglycemia
US7314859B2 (en) Compositions and methods for the prevention and control of insulin-induced hypoglycemia
US20230148019A1 (en) Use of ultrarapid acting insulin
JP2006514990A5 (fr)
US20170189492A1 (en) Use of Ultrarapid Acting Insulin
WO2014177623A1 (fr) Schéma d'administration d'un nouveau type
US8003605B2 (en) Minimising body weight gain in insulin treatment
CA2571030A1 (fr) Compositions et methodes pour la prevention et la regulation de l'hypoglycemie induite par l'insuline
US20230158116A1 (en) Use of human amylin analog polypeptides for providing superior glycemic control to type 1 diabetics
ZA200504944B (en) Compositions and methods for the prevention and control of insulin-induced hypoglycemia

Legal Events

Date Code Title Description
FZDE Discontinued